Mr. Wei Fu is an Independent Director at I-Mab, a Chairman at Everest Medicines Ltd., a Chief Executive Officer at Shanghai Kangshiqiao Business Consulting Co. Ltd., a Chief Executive Officer & Managing Partner at C-Bridge Capital Investment Management Ltd. and a Chief Executive Officer at Cbc Group Co. Ltd. He is on the Board of Directors at I-Mab, Ascletis Biopharmaceutical (Hangzhou) Co. Ltd., Everest Medicines (Singapore) Pte Ltd., Everest Medicines II BVI Ltd., Everest Medicines II HK Ltd., Everest Medicines II Ltd., Everonc Medicines Ltd. and Everonc Medicines, Inc. Mr. Fu was previously employed as a General Manager-Investment Department by Far East Horizon Ltd., a Head-Beijing Officer by Themes Investment Management Ltd., an Associate Director-Private Equity Department by Standard Chartered Business Consulting Beijing Co. Ltd., and a Non-Executive Director by Ascletis Pharma, Inc. He received his undergraduate degree from Nanyang Technological University.